Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 1/20 | 0.41 |
| ▸ | MTOR | P42345 | 1/20 | 0.41 |
| ▸ | PRKDC | P78527 | 1/20 | 0.41 |
| ▸ | JAK1 | P23458 | 5/20 | 0.39 |
| ▸ | JAK2 | O60674 | 2/20 | 0.39 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.38 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.38 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.38 |
| ▸ | OGFRL1 | Q5TC84 | 1/20 | 0.38 |
| ▸ | TNF | P01375 | 5/20 | 0.38 |
| ▸ | LITAF | Q99732 | 5/20 | 0.38 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.37 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.37 |
| ▸ | PDE4A | P27815 | 1/20 | 0.37 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.37 |
| ▸ | KDM4D | Q6B0I6 | 1/20 | 0.37 |
| ▸ | PLK1 | P53350 | 1/20 | 0.36 |
| ▸ | BTK | Q06187 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL869730 | 1.00 | PIK3CA (0.41) | PIK3CAMTORPRKDCJAK1JAK2 | |
| SCHEMBL871559 | 0.93 | PIK3CA (0.40) | PIK3CAMTORPRKDCJAK1JAK2 | |
| SCHEMBL871558 | 0.93 | PIK3CA (0.40) | PIK3CAMTORPRKDCJAK1JAK2 | |
| SCHEMBL4879082 | 0.91 | PDE4B (0.38) | TNFLITAFPDE4BPDE4DPDE4A | |
| SCHEMBL4879091 | 0.91 | PDE4B (0.38) | TNFLITAFPDE4BPDE4DPDE4A | |
| SCHEMBL4870413 | 0.90 | PDE4B (0.40) | JAK1JAK2TNFLITAFPDE4B | |
| SCHEMBL4870421 | 0.90 | PDE4B (0.40) | JAK1JAK2TNFLITAFPDE4B | |
| SCHEMBL870091 | 0.89 | PIK3CA (0.40) | PIK3CAMTORPRKDCJAK1JAK2 | |
| SCHEMBL8178696 | 0.89 | PIK3CA (0.40) | PIK3CAMTORPRKDCJAK1JAK2 | |
| SCHEMBL870811 | 0.88 | CKS1B (0.42) | PIK3CAMTORPRKDCJAK1JAK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2106396-B1 | CHEMICAL COMPOUNDS 637: PYRIDOPYRIMIDINEDIONES AS PDE4 INHIBITORS | ALCON RES LTD (US) | 2014-09-24 | — | — | EP | disclosed |
| US-20120077801-A1 | Chemical Compounds 637 | ALCON RESEARCH, LTD. | 2012-03-29 | — | — | US | disclosed |
| US-20100204203-A1 | Chemical Compounds 637: Pyridopyrimidinediones as PDE4 Inhibitors | ALCON RESEARCH, LTD. | 2010-08-12 | — | — | US | disclosed |
| US-20090124596-A1 | Chemical Compounds 637 | ALCON RESEARCH, LTD. | 2009-05-14 | — | — | US | disclosed |
| US-20080227797-A1 | Pyridopyrimidine Derivatives as Pde4 Inhibitors for the Treatment of Inflammatory and Immune Diseases | ASTRAZENECA AB (SE) | 2008-09-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120077801-A1 | Chemical Compounds 637 | PDE4A, PDE4B, PDE3B | PIK3CA 859/4885MTOR 3031/4885PRKDC 3085/4885 |
| US-20080227797-A1 | Pyridopyrimidine Derivatives as Pde4 Inhibitors for the Treatment of Inflammatory and Immune Diseases | PDE4A, PDE4B, PDE5A | PIK3CA 266/4885MTOR 1925/4885PRKDC 1923/4885 |
| US-20090124596-A1 | Chemical Compounds 637 | PDE4A, PDE4B, PDE3B | PIK3CA 859/4885MTOR 3031/4885PRKDC 3085/4885 |
| US-20100204203-A1 | Chemical Compounds 637: Pyridopyrimidinediones as PDE4 Inhibitors | PDE4A, PDE4B, PDE5A | PIK3CA 273/4885MTOR 2247/4885PRKDC 1819/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.